Leqvio (Inclisiran) Cost in Illinois 2026: Coverage, Savings, and Compounding Options

What Is the List Price of Leqvio in Illinois in 2026?

The Novartis wholesale acquisition cost (WAC) for Leqvio runs approximately $3,250 per single-use vial, which translates to roughly $540 per month when annualized across two doses per year. Cash-pay prices at Illinois retail pharmacies mirror that WAC closely. Patients without any assistance program or insurance coverage should expect to pay in that range at CVS, Walgreens, and independent Illinois pharmacies alike.

Annualizing the math helps clarify the real burden: two 284 mg subcutaneous injections per year (after the two loading doses at day 1 and day 90) [1] cost approximately $6,500 per year at list. That figure does not reflect what most insured patients actually pay, but it matters because it sets the denominator for every co-pay calculation and every Medicaid rebate negotiation.

The FDA approved inclisiran (Leqvio) on December 22, 2021, based on the ORION program data [2]. The approved label requires a diagnosis of either heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) plus the patient being on maximally tolerated statin therapy [2]. Illinois prescribers and pharmacies follow that same federal label without state-level restrictions beyond the Medicaid PA requirements described below.

Inclisiran works by inhibiting PCSK9 synthesis in the liver via small interfering RNA (siRNA) rather than binding circulating PCSK9 protein as monoclonal antibodies do [3]. That mechanism distinction matters clinically because each dose silences PCSK9 mRNA for roughly six months, producing durable LDL-C lowering with just two injections per year after loading [3].

How Much Did the Clinical Trials Show Inclisiran Lowers LDL-C?

Inclisiran produces approximately 50% LDL-C reduction. The key ORION-10 trial (N=1,561, United States population) found that inclisiran 284 mg reduced LDL-C by a mean of 52.3% from baseline at day 510 versus placebo (P<0.0001) [4]. The companion ORION-11 trial (N=1,617, European and South African population) reported a 49.9% LDL-C reduction at day 510 (P<0.0001) [4]. Both trials were published in the New England Journal of Medicine in 2020.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD on maximally tolerated statin therapy who require additional LDL-C lowering, PCSK9 inhibitors are recommended" [5]. Inclisiran fits that treatment tier as a PCSK9 inhibitor delivered by siRNA rather than antibody.

A pooled analysis of the ORION program (ORION-9, -10, -11; combined N>3,600) showed that inclisiran maintained LDL-C reductions of roughly 50% throughout the 18-month observation period with no attenuation of effect [6]. That durability is clinically meaningful because adherence to twice-yearly in-office injections is structurally superior to daily or monthly self-administered medications [6]. Research published in JAMA Cardiology found that patients who received clinician-administered injections had significantly better persistence at 12 months compared with self-injectable PCSK9 monoclonal antibodies [7].

Does Illinois Medicaid Cover Leqvio?

Illinois Medicaid (administered through the Illinois Department of Healthcare and Family Services, HFS) covers Leqvio with prior authorization. The PA criteria align broadly with the FDA label: documented HeFH or ASCVD, current maximally tolerated statin therapy, and an LDL-C above goal despite statin use [8].

Approval timelines vary. Standard PA decisions under Illinois Medicaid are required within 24 hours for urgent requests and within 72 hours for routine requests under Illinois Public Act 102-0258 [8]. Prescribers should submit documentation including a recent lipid panel (ideally within 90 days), a statin prescription history showing maximally tolerated dose, and the relevant diagnosis codes (E78.01 for FH, Z82.49 for family history of ASCVD).

Illinois Medicaid managed care organizations (MCOs) such as Meridian Health Plan, Molina Healthcare of Illinois, and Blue Cross Community Health Plans each have their own formulary tier placement and PA forms. The clinical criteria are similar across plans but the paperwork differs. Prescribers using Illinois telehealth platforms face no additional barriers; the state's telehealth parity law (Illinois Public Act 101-0528) requires MCOs to reimburse telehealth-delivered services at parity with in-person care [9].

Patients whose PA is denied have the right to appeal under the Illinois Administrative Code. The 2023 Illinois Department of Insurance guidance clarified that insurers must provide a written explanation of any PA denial for specialty drugs within five business days [10].

Which Commercial Insurance Plans Cover Leqvio in Illinois?

Most large commercial plans active in Illinois cover Leqvio at Tier 3 or Tier 4 specialty, meaning co-pays can range from $60 to $300 per dose before the Novartis savings program is applied. Blue Cross Blue Shield of Illinois, Aetna Illinois, Cigna Illinois, and United Healthcare all list inclisiran on their specialty formularies with PA requirements mirroring the FDA label [11].

The Centers for Medicare and Medicaid Services (CMS) added inclisiran to the Medicare Part D formulary coverage list, and CMS data from 2024 show that plans covering inclisiran under Part D assigned it to Tier 4 or Tier 5 in the majority of plan benefit packages [11]. Illinois has 27 stand-alone Part D plans as of 2025; patients should use the Medicare Plan Finder to identify which plans in their zip code cover inclisiran at the lowest net cost.

Medicare Part B coverage is also possible when inclisiran is administered in a physician's office or outpatient clinic. Under Part B, the drug is billed as a physician-administered drug (J-code J3490 or a dedicated J-code once assigned), and the patient owes the standard 20% coinsurance after the Part B deductible [12]. For a $3,250 dose, that 20% equals $650 per injection before any supplemental coverage. Medigap and Medicare Advantage plans may reduce or eliminate that coinsurance [12].

Employer-sponsored plans in Illinois that use a PBM (Express Scripts, CVS Caremark, OptumRx) typically require step therapy documentation showing a statin trial before approving a PCSK9 inhibitor. That step-therapy requirement is regulated under the Illinois Step Therapy Act (PA 100-0138), which mandates that insurers allow an exception within 72 hours when the prescriber demonstrates the step-therapy drug is clinically inappropriate [13].

How Does the Novartis Leqvio Savings Card Work in Illinois?

The Novartis patient support program, called "Leqvio Together," offers eligible commercially insured patients a $0 co-pay card. Illinois residents qualify under the same national terms: they must have commercial (non-government) insurance, be prescribed Leqvio for an FDA-approved indication, and not be enrolled in any state or federal program that pays for prescription drugs (Medicaid, Medicare, TRICARE, or VA) [14].

Eligible patients who enroll at the Novartis patient assistance portal can pay $0 per dose for up to 24 months in the first enrollment period, subject to annual renewal [14]. The program covers the co-pay gap between the insurer's reimbursement and the patient's share, up to the program maximum. Novartis has not publicly disclosed a per-claim maximum, but the practical effect for most Illinois commercial-plan members is a $0 out-of-pocket cost per injection.

For patients without insurance, Novartis also offers the Novartis Patient Assistance Program (PAP), which provides Leqvio free of charge to qualifying uninsured or underinsured patients who meet income criteria (generally household income at or below 400% of the federal poverty level) [14]. Illinois residents apply through the same portal with proof of income documentation.

Is Compounded Inclisiran Legal in Illinois?

Yes, compounded inclisiran is legally available in Illinois through licensed 503A compounding pharmacies, provided the compounding meets federal and state requirements. Illinois regulates pharmacy compounding under the Illinois Pharmacy Practice Act (225 ILCS 85) and state Board of Pharmacy rules, which align with FDA guidance on 503A compounders [15].

The key legal distinction is between 503A and 503B facilities. A 503A pharmacy compounds inclisiran for individual patients based on a valid prescription from a licensed Illinois prescriber [15]. A 503B outsourcing facility produces larger batches for office stock. As of the 2026 regulatory environment, inclisiran is not on the FDA's 503B bulk drug substances list, which means 503B compounders cannot legally produce it in advance without a patient-specific prescription [16].

The FDA's current position on compounded PCSK9 inhibitors reflects the agency's concern that compounded versions have not undergone the same stability, sterility, and bioequivalence testing as the FDA-approved product [16]. Illinois prescribers must weigh that regulatory nuance carefully and document their clinical rationale when writing a prescription to a 503A compounder.

Cost comparison is stark. Where compounded inclisiran is available through licensed Illinois 503A pharmacies, reported cash prices run significantly below the Novartis WAC, with some compounding pharmacies quoting costs near $0 per month when comparing annualized costs, or more precisely, a fraction of the $6,500 annual list cost. Patients should verify that any pharmacy they use is licensed by the Illinois Board of Pharmacy and registered with the FDA as required [15].

Can Illinois Patients Get Leqvio Through Telehealth?

Yes. Illinois permits telehealth prescribing of Leqvio without a prior in-person visit, provided the prescriber meets the standard of care for evaluation (reviewing a complete lipid panel, statin history, and cardiovascular risk documentation) [9]. The Illinois telehealth parity law (PA 101-0528) requires commercial insurers to cover telehealth-delivered clinical services at parity with in-person services [9].

The physical injection, however, must be administered in a clinical setting. Inclisiran is a subcutaneous injection delivered by a trained healthcare professional, not by the patient at home. Illinois telehealth workflows for Leqvio typically follow this pathway: the prescriber evaluates the patient via video visit, generates the prescription, and the patient then receives the injection at a participating infusion center, primary care office, or cardiologist's office. Some Illinois health systems have implemented standing-order protocols that allow a nurse or medical assistant to administer the injection after a telehealth visit is documented.

The HealthRX Illinois Inclisiran Access Framework identifies four patient access pathways based on insurance status. Commercially insured patients with Novartis savings card enrollment pay $0 per injection. Medicare Part B patients with supplemental coverage pay $0 to $130 per injection depending on their Medigap or Medicare Advantage plan. Illinois Medicaid patients who obtain PA pay $0 to $3 per injection under standard Medicaid cost-sharing. Uninsured patients may access the Novartis PAP at no cost if income-qualified, or may pursue 503A compounded inclisiran with cash pricing.

What Is the Cheapest Way to Get Leqvio in Illinois?

The lowest-cost pathway depends entirely on insurance status. For commercially insured patients, enrolling in the Novartis "Leqvio Together" savings card before the first injection brings the cost to $0 [14]. The card is activated before the prescription is adjudicated at the pharmacy or infusion center.

Illinois Medicaid beneficiaries who obtain PA pay the standard Medicaid cost-sharing, typically $0 to $3 per prescription fill, making this the lowest possible cost for eligible patients [8]. The barrier is documentation and PA approval time, not the cost itself once approved.

Uninsured patients in Illinois face a $6,500 annual cash price at WAC. The two practical alternatives are the Novartis PAP (income-qualified, free drug) or a licensed 503A compounding pharmacy. Patients pursuing compounding should request the pharmacy's certificate of analysis for each batch, confirming potency and sterility testing, before accepting any compounded product [15].

Medicare patients should compare Part B administration versus Part D pharmacy coverage in their specific plan. A 2023 analysis in JAMA Network Open found that out-of-pocket costs for PCSK9 inhibitors varied by more than $1,200 per year across Medicare Part D plans in the same geographic region, confirming that plan selection materially affects cost [17].

How Does Inclisiran Compare to Other PCSK9 Inhibitors on Cost?

The two monoclonal antibody PCSK9 inhibitors available in the United States are evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron). Both require biweekly or monthly self-injections versus inclisiran's twice-yearly schedule.

Evolocumab WAC runs approximately $600 per month ($7,200/year) for the 140 mg biweekly dosing, and alirocumab WAC runs approximately $550 per month for 150 mg biweekly dosing [18]. Inclisiran at $540/month annualized is comparable on list price but the dosing schedule is a structural advantage for adherence-sensitive patients.

The FOURIER trial (N=27,564) showed evolocumab 140 mg biweekly reduced LDL-C by 59% and reduced the risk of major adverse cardiovascular events (MACE) by 15% relative to placebo (P<0.001) [19]. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab 75 mg to 150 mg reduced LDL-C by 54.7% and reduced MACE risk by 15% (P<0.001) [20]. Inclisiran's ORION-10 and ORION-11 trials demonstrated equivalent LDL-C reductions but were not powered for MACE outcomes; the ongoing ORION-4 outcomes trial is expected to report cardiovascular event data [4].

For Illinois patients choosing between agents, formulary tier placement at their specific insurer is often the deciding factor. A cardiologist writing the first prescription should check the plan formulary before selecting an agent, because tier placement differences can translate to hundreds of dollars per year in co-pay differences even when list prices are similar [11].

What Documentation Do Illinois Prescribers Need for PA Approval?

Prior authorization for Leqvio through Illinois commercial plans and Medicaid requires a specific documentation package. Missing even one element is the most common reason for initial PA denial.

Required documentation typically includes: a lipid panel dated within 90 days showing LDL-C above goal; a current statin prescription at the highest tolerated dose; the ICD-10 diagnosis code for ASCVD (I25.10 for chronic ischemic heart disease, I63.x for ischemic stroke, or I73.9 for peripheral arterial disease) or HeFH (E78.01); and a note documenting that the patient has been on statin therapy for at least 90 days without reaching LDL-C goal [5].

Some Illinois commercial plans additionally require documentation of a prior trial of ezetimibe (generic; ~$10/month) before approving a PCSK9 inhibitor. The ACC/AHA cholesterol guidelines support this sequencing as a cost-effective strategy, noting that ezetimibe added to statin lowers LDL-C by an additional 13% to 20% [5]. If ezetimibe has been tried and the LDL-C remains above goal, documenting that trial strengthens the PA.

The Illinois Step Therapy Act exempts patients from step-therapy requirements when the required drug is contraindicated, likely to cause adverse effects, or has already been tried and failed [13]. For patients with a documented statin-associated muscle syndrome (SAMS) preventing maximally tolerated statin use, that exemption may accelerate PA approval.

The FDA label specifies inclisiran 284 mg subcutaneous injection administered initially, again at three months, and then every six months thereafter [2]. The PA must cover that dosing schedule; a PA written for a single dose will not cover the maintenance injections.

Monitoring and Follow-Up After Starting Leqvio in Illinois

After the first inclisiran injection, a fasting lipid panel at 90 days (before the second loading dose) confirms the LDL-C response. ORION-10 data showed that LDL-C nadir occurs at approximately day 30 to 60 post-injection and then rises slightly before the next dose, but remains well below baseline throughout the dosing interval [4].

The American College of Cardiology recommends checking a fasting lipid panel four to twelve weeks after initiating or changing lipid-lowering therapy, then every three to twelve months thereafter [5]. For inclisiran patients on a twice-yearly injection schedule, an annual lipid panel timed approximately 30 days after each injection captures the near-nadir response and satisfies most PA renewal requirements [5].

Hepatic transaminases should be checked at baseline and periodically during therapy per the FDA label, as inclisiran is hepatically administered via its siRNA mechanism and mild transaminase elevations have been observed in clinical trials [2]. Injection-site reactions occurred in 8.2% of inclisiran-treated patients versus 1.8% of placebo-treated patients in ORION-10, though most were mild [4].

Illinois patients receiving inclisiran through a telehealth platform should confirm that their follow-up lipid panels are ordered and that results are reviewed before each subsequent injection authorization. A fasting lipid panel showing LDL-C at goal (below 70 mg/dL for high-risk ASCVD patients, or below 55 mg/dL for very high-risk patients per 2022 ACC/AHA criteria) [5] is the most straightforward evidence for PA renewal.